Alabama



Grade	Recommendations to Improve Patient Access
B	 Remove prior authorization for HCV treatment. Remove retreatment restriction. Remove additional restrictions as described below.

State Overview

As of February 2022, 1,101,645 individuals were enrolled in Medicaid and CHIP.¹ It is estimated that as of 2016, 30,700 people were living with HCV in Alabama.² Alabama does not contract with any managed care organizations (MCOs).³

The Alabama Medicaid Preferred Drug List includes Epclusa, Harvoni, Mavyret, Zepatier, sofosbuvir/velpatasvir, and ledipasvir/sofosbuvir.⁴

Deductio	ons	Policy	
Prior Authorization	-8	Prior authorization is required for all Direct-Acting Antiviral (DAA) HCV treatment regimens. ⁵	
Fibrosis Restrictions		Alabama Medicaid does not impose fibrosis restrictions. ⁶	
Substance Use Restrictions		Alabama Medicaid does not impose substance use restrictions. ⁷	
Prescriber Restrictions		Alabama Medicaid does not impose prescriber restrictions. ⁸	
Retreatment Restrictions	-8	Alabama Medicaid imposes retreatment restrictions. Alabama Medicaid only provides one course of treatment per lifetime. ⁹	
Access in Managed Care		Alabama Medicaid does not contract with MCOs. ¹⁰	
Additional Restrictions	-4	 Alabama Medicaid imposes additional restrictions as follows: Documentation of genotype.¹¹ Documentation of adherence counseling. Patients are required to sign a contract stating: "I understand that Medicaid will pay for only one course of medicine. If I do not take my medicine as prescribed, I will not be approved for another course of therapy."¹² 	
Total Deductions		Total Score [100-Deductions] Grade	
-20		80 B	

Contact Your State Officials

Medicaid Office¹³: Stephanie Azar, Commissioner, Alabama Medicaid Agency 501 Dexter Avenue, Montgomery, AL 36103; Telephone: (334)242-5600; Email Address: stephanie.azar@medicaid.alabama.gov

Pharmacy & Therapeutics Committee¹⁴: Kelli Littlejohn Newman, Director, Clinical Services and Support 501 Dexter Avenue, P.O. Box 5624. Montgomery, AL 36103-5624; Telephone: (334)353-4525; Fax: (334)353-5623; Email Address: Kelli.littlejohn@medicaid.alabama.gov

Key	Sources
-----	---------

Preferred Drug List: Alabama Medicaid, Preferred Drug List (Oct. 1, 2022).

Prior Authorization Form: <u>Alabama Medicaid, Hepatitis C Antiviral Agents PA Request Form (Oct. 1, 2022)</u>. Clinical Criteria: <u>Alabama Medicaid, Hepatitis C Antiviral Agents Criteria Instructions (Oct. 1, 2022)</u>. Patient Consent Form: <u>Alabama Medicaid, Pharmacy Patient Consent Form: Hepatitis C Agents (Oct. 1, 2022)</u>.

⁴ Preferred Drug List.

https://perma.cc/X7FE-ZHER.

¹¹ Prior Authorization Form.



¹ Centers for Medicare & Medicaid Services, Medicaid & CHIP in Alabama: https://perma.cc/PL4P-6SPV.

² HepVu, Local Data: Alabama (Jan. 2022): https://perma.cc/24UP-PVBS.

³ Kaiser Family Foundation, Share of Medicaid Population Covered under Different Delivery Systems (Jul. 2021),

https://perma.cc/X7FE-ZHER.

⁵ Prior Authorization Form.

⁶ Prior Authorization Form.

⁷ Alabama Medicaid, Provider Alerts: Changes to Hepatitis C Prior Authorization Criteria (Sept. 27, 2022), https://perma.cc/9F6D-FBEW.

⁸ Prior Authorization Form.

⁹ Prior Authorization Form.

¹⁰ Kaiser Family Foundation, Share of Medicaid Population Covered under Different Delivery Systems (Jul. 2021),

¹² Patient Consent Form.

¹³ National Association of Medicaid Directors, Medicaid Directors: https://perma.cc/RK6K-TFKK.

¹⁴ Contact Information, Alabama Medicaid P&T Committee: https://perma.cc/JA2S-3UA7.